GENELUX CORPORATION Increase Decrease In Operating Lease Liability
GENELUX CORPORATION (GNLX) reported Increase Decrease In Operating Lease Liability of -$163.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-13
- GENELUX CORPORATION increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$76.00K.
- GENELUX CORPORATION increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$87.00K.
- GENELUX CORPORATION increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$93.00K.
- GENELUX CORPORATION increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$83.00K.
- GENELUX CORPORATION increase decrease in operating lease liability for fiscal 2025 was -$337.00K.
- GENELUX CORPORATION increase decrease in operating lease liability for fiscal 2024 was -$651.00K.
- GENELUX CORPORATION increase decrease in operating lease liability for fiscal 2023 was -$523.00K.
- GENELUX CORPORATION increase decrease in operating lease liability for fiscal 2022 was -$389.00K.
| Period end | Increase Decrease In Operating Lease Liability | Increase Decrease In Operating Lease Liability 1 month | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$76.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$163.00K 10-Q · filed 2026-08-13 | -$256.00K derived: sum of 3 quarters · filed 2026-08-13 | -$339.00K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | -$87.00K 10-Q · filed 2026-05-07 | -$180.00K derived: sum of 2 quarters · filed 2026-05-07 | -$263.00K derived: sum of 3 quarters · filed 2026-05-07 | -$343.00K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | -$93.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$176.00K derived: sum of 2 quarters · filed 2026-03-19 | -$256.00K derived: sum of 3 quarters · filed 2026-08-13 | -$337.00K 10-K · filed 2026-03-19 | ||
| 2025-09-30 | -$83.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$163.00K derived: sum of 2 quarters · filed 2026-08-13 | -$244.00K 10-Q · filed 2025-11-05 | -$415.00K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | -$80.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$161.00K 10-Q · filed 2026-08-13 | -$332.00K derived: sum of 3 quarters · filed 2026-08-13 | -$500.00K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | -$81.00K 10-Q · filed 2026-05-07 | -$252.00K derived: sum of 2 quarters · filed 2026-05-07 | -$420.00K derived: sum of 3 quarters · filed 2026-05-07 | -$584.00K derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | -$171.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$339.00K derived: sum of 2 quarters · filed 2026-03-19 | -$503.00K derived: sum of 3 quarters · filed 2026-03-19 | -$651.00K 10-K · filed 2026-03-19 | ||
| 2024-09-30 | -$168.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$332.00K derived: sum of 2 quarters · filed 2025-11-05 | -$480.00K 10-Q · filed 2025-11-05 | -$572.00K derived: sum of 4 quarters · filed 2025-11-05 | ||
| 2024-06-30 | -$164.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$312.00K 10-Q · filed 2025-08-07 | -$404.00K derived: sum of 3 quarters · filed 2025-08-07 | -$570.00K derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | -$148.00K 10-Q · filed 2025-05-06 | -$240.00K derived: sum of 2 quarters · filed 2025-05-06 | -$406.00K derived: sum of 3 quarters · filed 2025-05-06 | -$557.00K derived: sum of 4 quarters · filed 2025-05-06 | ||
| 2023-12-31 | -$92.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$258.00K derived: sum of 2 quarters · filed 2025-03-28 | -$409.00K derived: sum of 3 quarters · filed 2025-03-28 | -$523.00K 10-K · filed 2025-03-28 | ||
| 2023-09-30 | -$166.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$317.00K derived: sum of 2 quarters · filed 2024-11-14 | -$431.00K 10-Q · filed 2024-11-14 | -$537.00K derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-07-31 | $208.00K 10-K · filed 2025-03-28 | |||||
| 2023-06-30 | -$151.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$265.00K 10-Q · filed 2024-08-14 | -$371.00K derived: sum of 3 quarters · filed 2024-08-14 | -$470.00K derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | -$114.00K 10-Q · filed 2024-05-09 | -$220.00K derived: sum of 2 quarters · filed 2024-05-09 | -$319.00K derived: sum of 3 quarters · filed 2024-05-09 | -$423.00K derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2023-02-28 | $637.00K 10-Q · filed 2024-05-09 | |||||
| 2022-12-31 | -$106.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$205.00K derived: sum of 2 quarters · filed 2024-03-29 | -$309.00K derived: sum of 3 quarters · filed 2024-03-29 | -$389.00K 10-K · filed 2024-03-29 | ||
| 2022-09-30 | -$99.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$203.00K derived: sum of 2 quarters · filed 2023-11-14 | -$283.00K 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | -$104.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$184.00K 10-Q · filed 2023-08-14 | ||||
| 2022-04-30 | $686.00K 10-Q · filed 2024-05-09 | |||||
| 2022-03-31 | -$80.00K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |